Collectively, based on the lack of a correlation between mRNA expression and patient prognosis in primary GBM and a significant association in recurrent GBM, FCGR2B is a unique candidate from the list of potential oncogenic regulators that play a fundamental role in recurrent GBM. Here, FCGR2B is linked to glioblastoma.